Digital healthcare company iRhythm Technologies has signed a licensing agreement with health monitoring firm BioIntelliSense to enhance its ambulatory cardiac monitoring (ACM) capabilities.
The partnership will focus on advancing and commercialising specific patented sensor technologies in the ACM field.
Under the agreement, iRhythm Technologies has been granted an exclusive licence to BioIntelliSense’s patented pulse oximetry, accelerometer, and non-invasive blood pressure technologies.
These technologies will be integrated into the digital healthcare firm’s ACM products and services.
As part of the collaboration, BioIntelliSense will receive an upfront payment and may earn additional compensation based on the achievement of future technology validation and regulatory milestones.
Additionally, the health monitoring company will be entitled to royalties on annual net sales of products and services with these licensed technologies.
iRhythm Technologies president and CEO Quentin Blackford said: “We believe that the licensed technology from BioIntelliSense can advance our premium positioning within ACM and further enables us to enter other adjacent indications such as obstructive sleep apnoea over time.
“By incorporating medical grade, connected, multi-sensor capabilities, we believe iRhythm will be well positioned to deliver broad clinical insights that improve patient outcomes, enhance clinical and operational efficiency, and reduce costs to the healthcare system.”
BioIntelliSense provides a broad range of vital sign indicators designed to enhance patient safety and monitoring effectiveness, both in hospitals and at home. Its portfolio includes medical-grade wearable devices and data services that enable early detection of adverse trends.
BioButton, the firm’s US Food and Drug Administration (FDA)-cleared wearable device, offers personalised notifications based on patient trends, including resting heart rate, respiratory rate, and skin temperature.
Additionally, BioIntelliSense features patented advancements in oximetry through its white-light enhanced pulse oximetry (SpO2) sensor chipset. The technology allows accurate measurement of blood oxygen levels across various skin tones and offers motion tolerance.
Previously, the company partnered with Medtronic on distribution rights for the BioButton device in 2022.
BioIntelliSense founder and CEO James Mault said: “Through the integration of advanced biosensors and algorithmic-based analytics, we can collectively address a critical gap in the current healthcare system, by providing clinicians with more timely and actionable information to facilitate earlier clinical intervention and better, safer patient care.”
